Literature DB >> 2188927

Discrepancy between cytotoxicity and DNA interstrand crosslinking of carboplatin and cisplatin in vivo.

W DeNeve1, F Valeriote, E Tapazoglou, C Everett, A Khatana, T Corbett.   

Abstract

We used the method of alkaline elution to compare quantitatively the DNA lesions produced by cisplatin and carboplatin in the AKR leukemia in vivo. These data were compared with cytotoxicity of each drug in the same animal model and in a solid tumor murine model (colon 26). DNA-protein and DNA-DNA interstrand crosslinks were formed in similar proportions by both drugs when peak values of crosslinking were compared. No clear difference in the rate of formation of both types of crosslinks could be observed between these drugs. On a molar basis a 3- to 4-fold more carboplatin had to be given to obtain equivalent frequencies of both types of crosslinks. In contrast, to obtain equitoxicity in the same animal tumor model, 13 fold higher doses of carboplatin had to be given. This difference in cytotoxicity between both drugs is comparable to the difference measured in colon 26 in vivo (16 fold). Both values are in the range of literature data (10-25 fold) dealing with the relative potency of cisplatin and carboplatin in murine tumor models.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2188927     DOI: 10.1007/bf00216920

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  18 in total

1.  Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure.

Authors:  T H Corbett; D P Griswold; B J Roberts; J C Peckham; F M Schabel
Journal:  Cancer Res       Date:  1975-09       Impact factor: 12.701

2.  Improved microfluorometric DNA determination in biological material using 33258 Hoechst.

Authors:  C F Cesarone; C Bolognesi; L Santi
Journal:  Anal Biochem       Date:  1979-11-15       Impact factor: 3.365

3.  In vitro stability, plasma protein binding and blood cell partitioning of 14C-carboplatin.

Authors:  R C Gaver; A M George; G Deeb
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

Review 4.  Chemotherapy of ovarian cancer.

Authors:  R F Ozols; R C Young
Journal:  Semin Oncol       Date:  1984-09       Impact factor: 4.929

5.  Immunocytochemical detection of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in rodent tissue sections.

Authors:  P M Terheggen; B G Floot; E Scherer; A C Begg; A M Fichtinger-Schepman; L den Engelse
Journal:  Cancer Res       Date:  1987-12-15       Impact factor: 12.701

6.  Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate.

Authors:  D L Bodenner; P C Dedon; P C Keng; J C Katz; R F Borch
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701

7.  Influence of WR2721 on DNA cross-linking by nitrogen mustard in normal mouse bone marrow and leukemia cells in vivo.

Authors:  W J DeNeve; C K Everett; J E Suminski; F A Valeriote
Journal:  Cancer Res       Date:  1988-11-01       Impact factor: 12.701

8.  DNA cross-linking and cytotoxicity induced by cis-diamminedichloroplatinum(II) in human normal and tumor cell lines.

Authors:  G Laurent; L C Erickson; N A Sharkey; K W Kohn
Journal:  Cancer Res       Date:  1981-09       Impact factor: 12.701

9.  Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma.

Authors:  B D Evans; K S Raju; A H Calvert; S J Harland; E Wiltshaw
Journal:  Cancer Treat Rep       Date:  1983-11

10.  Effect of diethyldithiocarbamate on cis-diamminedichloroplatinum(II)-induced cytotoxicity, DNA cross-linking, and gamma-glutamyl transpeptidase inhibition.

Authors:  D L Bodenner; P C Dedon; P C Keng; R F Borch
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701

View more
  2 in total

Review 1.  Clinical pharmacokinetics of carboplatin.

Authors:  W J van der Vijgh
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

Review 2.  Inhibition of transcription by platinum antitumor compounds.

Authors:  Ryan C Todd; Stephen J Lippard
Journal:  Metallomics       Date:  2009       Impact factor: 4.526

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.